NanoViricides to present at D. Boral Capital Global Conference May 7 in NYC

NanoViricides, Inc., a clinical-stage antiviral company, announced its participation in the D. Boral Capital Global Conference on May 7, 2026, in New York City. The company's President, Dr. Anil R. Diwan, will hold one-on-one meetings to discuss their broad-spectrum antiviral drug NV-387, which has received Orphan Drug Designation by the FDA, potentially granting market exclusivity and other benefits. NV-387 shows promise against multiple respiratory viruses including Influenza, RSV, and Coronaviruses. This event highlights NanoViricides' efforts to advance their innovative antiviral treatments and engage with investors and partners.